MA46042A - Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin - Google Patents
Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallinInfo
- Publication number
- MA46042A MA46042A MA046042A MA46042A MA46042A MA 46042 A MA46042 A MA 46042A MA 046042 A MA046042 A MA 046042A MA 46042 A MA46042 A MA 46042A MA 46042 A MA46042 A MA 46042A
- Authority
- MA
- Morocco
- Prior art keywords
- disubstituted
- steroid
- pyrazolyl
- crystalline
- Prior art date
Links
- VVUQRXPUVKXAIO-XFUVECHXSA-N 19-nor-5-androstenediol Chemical compound C1[C@@H](O)CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC=C21 VVUQRXPUVKXAIO-XFUVECHXSA-N 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46042A true MA46042A (fr) | 2019-07-03 |
Family
ID=59772778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046042A MA46042A (fr) | 2016-08-23 | 2017-08-23 | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US11236121B2 (fr) |
| EP (2) | EP3504189A1 (fr) |
| JP (3) | JP2019524853A (fr) |
| KR (2) | KR20190040043A (fr) |
| CN (4) | CN110088091A (fr) |
| AR (3) | AR109393A1 (fr) |
| AU (2) | AU2017315682B2 (fr) |
| BR (1) | BR112019003637A2 (fr) |
| CA (1) | CA3034262A1 (fr) |
| CL (2) | CL2019000477A1 (fr) |
| CO (1) | CO2019002596A2 (fr) |
| EA (1) | EA201990565A1 (fr) |
| EC (1) | ECSP19020141A (fr) |
| IL (2) | IL302480A (fr) |
| JO (3) | JOP20190022B1 (fr) |
| MA (1) | MA46042A (fr) |
| MX (2) | MX393240B (fr) |
| MY (1) | MY200479A (fr) |
| PE (2) | PE20190915A1 (fr) |
| PH (1) | PH12019500375A1 (fr) |
| SG (1) | SG11201901445TA (fr) |
| TW (3) | TWI808945B (fr) |
| WO (1) | WO2018039378A1 (fr) |
| ZA (1) | ZA201901051B (fr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3572417B1 (fr) | 2011-10-14 | 2025-12-17 | Sage Therapeutics, LLC | Composés de 19-nor prégnane disubstitués 3,3, compositions et leurs utilisations |
| CA2882708A1 (fr) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Procedes de traitement de l'epilepsie ou d'un etat de mal epileptique |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| EP2986624B1 (fr) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs 19-nor et pour l'utilisation thérapeutique |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| ME03809B (fr) | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | Compositions et méthodes pour traiter des troubles du snc |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| WO2016082789A1 (fr) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions et procédés pour traiter des troubles du snc |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| EP4155314A1 (fr) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions et leurs utilisations |
| WO2018013615A1 (fr) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| EP3504189A1 (fr) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
| WO2019051264A1 (fr) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et leurs méthodes d'utilisation |
| CA3075872A1 (fr) * | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | Steroide c21-n-pyrazolyl c3,3-disubstitue 19 nor, et procedes d'utilisation de ce dernier |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| CA3103421A1 (fr) * | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | 19-nor steroide c21-n-pyrazolyle disubstitue en c3,3 et procedes d'utilisation de celui-ci |
| KR20250174100A (ko) | 2018-12-05 | 2025-12-11 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| CN111770915A (zh) * | 2019-01-31 | 2020-10-13 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| WO2020242772A1 (fr) | 2019-05-28 | 2020-12-03 | Teva Czech Industries S.R.O | Formes à l'état solide de sage-217 et procédés de préparation associés |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CN118027131A (zh) * | 2019-08-07 | 2024-05-14 | 上海翰森生物医药科技有限公司 | 一种甾族类衍生物调节剂的盐及其晶型 |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| EP4125921A1 (fr) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Utilisation d'agents pour le traitement d'affections respiratoires |
| KR20230041049A (ko) * | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| WO2022072620A1 (fr) * | 2020-10-01 | 2022-04-07 | Eliem Therapeutics (UK) Ltd | Méthodes de traitement de la fibromyalgie à l'aide de stéroïdes neuroactifs |
| KR20230136599A (ko) | 2021-01-28 | 2023-09-26 | 세이지 테라퓨틱스, 인크. | 성 기능장애의 치료를 위한 신경활성 스테로이드의용도 |
| US20240245711A1 (en) * | 2021-03-17 | 2024-07-25 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| EP4329769A1 (fr) | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | Stéroïde neuroactif destiné à être utilisé dans le traitement d'un trouble dépressif majeur et de la dépression post-partum chez une femme allaitante |
| WO2022232504A1 (fr) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Stéroïde c21-n-pyrazolyl disubstitué en c3,3 19-nor destiné à être utilisé dans le traitement de la dépression majeure et de la dépression post-partum |
| PE20240780A1 (es) | 2021-07-28 | 2024-04-17 | Sage Therapeutics Inc | Formas cristalinas de un esteroide neuroactivo |
| IL315023A (en) | 2022-02-16 | 2024-10-01 | Sage Therapeutics Inc | Neuroactive steroids for treatment of cns-related disorders |
| WO2023163879A1 (fr) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs pour le traitement de maladies ou d'états gastro-intestinaux |
| WO2026055127A2 (fr) | 2024-09-04 | 2026-03-12 | Sage Therapeutics, Inc., A Wholly Owned Subsidiary Of Supernus Pharmaceuticals, Inc. | Procédé de production d'un modulateur de récepteur gaba |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| EP1248869A2 (fr) * | 2000-01-07 | 2002-10-16 | Transform Pharmaceuticals, Inc. | Formation, identification et analyse a productivites elevees de formes solides diverses |
| PL215006B1 (pl) | 2002-02-08 | 2013-10-31 | Ono Pharmaceutical Co | Krystaliczna postac pochodnej piperydyny oraz jej zastosowanie |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| WO2013043985A1 (fr) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Huiles comestibles favorisant l'administration de stéroïdes administrés par voie orale |
| EP3572417B1 (fr) | 2011-10-14 | 2025-12-17 | Sage Therapeutics, LLC | Composés de 19-nor prégnane disubstitués 3,3, compositions et leurs utilisations |
| EP2806877B2 (fr) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Formulations de stéroïdes neuroactifs comprenant un complexe d'allopregnanolone et de sulfobutyl ether beta-cyclodextrine |
| US20150175651A1 (en) | 2012-06-15 | 2015-06-25 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| CA2882708A1 (fr) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Procedes de traitement de l'epilepsie ou d'un etat de mal epileptique |
| WO2014058736A1 (fr) | 2012-10-08 | 2014-04-17 | Washington University | Stéroïdes neuroactifs 19-alcoxy-17(20)-z-vinylcyano-substitués, promédicaments associés et méthodes de traitement les utilisant |
| AU2013352141B2 (en) | 2012-11-30 | 2018-04-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| HUE039057T2 (hu) | 2012-12-18 | 2018-12-28 | Univ Washington | Kezelési eljárásokban alkalmazható neuroaktív 19-alkoxi-17-szubsztituált szteroidok |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| EP2986624B1 (fr) | 2013-04-17 | 2020-03-25 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs 19-nor et pour l'utilisation thérapeutique |
| US20160068563A1 (en) | 2013-04-17 | 2016-03-10 | Boyd L. Harrison | 19-nor neuroactive steroids and methods of use thereof |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| AU2014308621C1 (en) | 2013-08-23 | 2022-01-06 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2805598T3 (es) | 2014-05-29 | 2021-02-12 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN117024501A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| ME03809B (fr) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | Compositions et méthodes pour traiter des troubles du snc |
| WO2016082789A1 (fr) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions et procédés pour traiter des troubles du snc |
| RS61530B1 (sr) | 2015-01-26 | 2021-04-29 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns |
| EP4155314A1 (fr) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions et leurs utilisations |
| EP3280420B1 (fr) | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions et méthodes permettant de traiter des troubles du snc |
| AR105044A1 (es) | 2015-06-18 | 2017-08-30 | Sage Therapeutics Inc | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| CA2998134A1 (fr) | 2015-09-08 | 2017-03-16 | Viewpoint Therapeutics, Inc. | Composes et formulations pour traiter les maladies ophthalmiques |
| AU2016338672A1 (en) | 2015-10-16 | 2018-04-12 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| MA43284A (fr) | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| KR20240157128A (ko) | 2016-03-08 | 2024-10-31 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드, 조성물, 및 그의 용도 |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| WO2018013615A1 (fr) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| EP3504189A1 (fr) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (fr) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | Méthodes de traitement de l'épilepsie et d'affections associées à kcnti |
| US11285139B2 (en) | 2017-08-31 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Treatment of CNS conditions |
| WO2019051264A1 (fr) | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et leurs méthodes d'utilisation |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| CA3075872A1 (fr) | 2017-09-14 | 2019-03-21 | Sage Therapeutics, Inc. | Steroide c21-n-pyrazolyl c3,3-disubstitue 19 nor, et procedes d'utilisation de ce dernier |
| MY204493A (en) | 2017-11-10 | 2024-08-30 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disorders |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| BR112020012761A2 (pt) | 2017-12-22 | 2021-02-17 | Sage Therapeutics, Inc. | composições e métodos para o tratamento de distúrbios do snc |
| MX2020006599A (es) | 2017-12-22 | 2020-11-06 | Sage Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
| TW201930269A (zh) | 2018-01-12 | 2019-08-01 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
| CA3103421A1 (fr) | 2018-06-12 | 2019-12-19 | Sage Therapeutics, Inc. | 19-nor steroide c21-n-pyrazolyle disubstitue en c3,3 et procedes d'utilisation de celui-ci |
| EP4321519B1 (fr) | 2018-10-12 | 2026-04-08 | Sage Therapeutics, LLC | Stéroïdes neuroactifs substitués en position 10 avec un groupe cyclique pour une utilisation dans le traitement de troubles du système nerveux central |
| ES3039267T3 (en) | 2018-10-19 | 2025-10-20 | Sage Therapeutics Inc | 9(11)-unsaturated neuroactive steroids and their methods of use |
| KR20250174100A (ko) | 2018-12-05 | 2025-12-11 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드 및 이의 사용 방법 |
| WO2020132504A1 (fr) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs de 3.alpha.-hydroxy-17.bêta.-amide et compositions associées |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| CN114729000A (zh) | 2019-06-27 | 2022-07-08 | 萨奇治疗股份有限公司 | 用于治疗cns病症的化合物 |
| JP7754725B2 (ja) | 2019-06-27 | 2025-10-15 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を治療するための組成物及び方法 |
| CA3143509A1 (fr) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions et methodes de traitement de troubles du snc |
| KR20220112803A (ko) | 2019-12-05 | 2022-08-11 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2021188778A2 (fr) | 2020-03-18 | 2021-09-23 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et leurs procédés d'utilisation |
| EP4125921A1 (fr) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Utilisation d'agents pour le traitement d'affections respiratoires |
| US20230250129A1 (en) | 2020-06-24 | 2023-08-10 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| KR20230041049A (ko) | 2020-07-20 | 2023-03-23 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법 |
| WO2022115381A1 (fr) | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Onc. | Compositions et méthodes de traitement de troubles du système nerveux central et application associée |
| KR20230136599A (ko) | 2021-01-28 | 2023-09-26 | 세이지 테라퓨틱스, 인크. | 성 기능장애의 치료를 위한 신경활성 스테로이드의용도 |
| WO2022177718A1 (fr) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Utilisation d'un stéroïde neuroactif pour le traitement d'un dysfonctionnement sexuel |
| US20240245711A1 (en) | 2021-03-17 | 2024-07-25 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| JP2024513581A (ja) | 2021-04-12 | 2024-03-26 | セージ セラピューティクス， インコーポレイテッド | 本態性振戦の治療 |
| WO2022232504A1 (fr) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Stéroïde c21-n-pyrazolyl disubstitué en c3,3 19-nor destiné à être utilisé dans le traitement de la dépression majeure et de la dépression post-partum |
| EP4329769A1 (fr) | 2021-04-29 | 2024-03-06 | Sage Therapeutics, Inc. | Stéroïde neuroactif destiné à être utilisé dans le traitement d'un trouble dépressif majeur et de la dépression post-partum chez une femme allaitante |
| IL315023A (en) | 2022-02-16 | 2024-10-01 | Sage Therapeutics Inc | Neuroactive steroids for treatment of cns-related disorders |
| WO2023163879A1 (fr) | 2022-02-28 | 2023-08-31 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs pour le traitement de maladies ou d'états gastro-intestinaux |
-
2017
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/fr not_active Withdrawn
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/fr not_active Ceased
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/fr active Pending
- 2017-08-23 CA CA3034262A patent/CA3034262A1/fr active Pending
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es not_active Application Discontinuation
- 2017-08-23 MY MYPI2019000844A patent/MY200479A/en unknown
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 TW TW112101437A patent/TWI854445B/zh active
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Ceased
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 IL IL315950A patent/IL315950B1/en unknown
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 MX MX2019002193A patent/MX393240B/es unknown
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 TW TW113108231A patent/TWI904593B/zh active
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 PE PE2024000634A patent/PE20241580A1/es unknown
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt not_active Application Discontinuation
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko active Pending
-
2018
- 2018-03-01 JO JOJO/P/2022/0305A patent/JOP20220305A1/ar unknown
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
- 2022-11-10 JO JOJO/P/2022/0304A patent/JOP20220304A1/ar unknown
-
2023
- 2023-08-24 US US18/455,324 patent/US12358942B2/en active Active
-
2024
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja not_active Withdrawn
-
2025
- 2025-06-11 US US19/234,808 patent/US20250304615A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46042A (fr) | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin | |
| IL278487B (en) | 19- nor c3, 3- dimethomer c21- n- pyrazole Steroids and methods of using them | |
| IL258844A (en) | Methods for culturing cells and kits and apparatus for same | |
| NO2022020I1 (no) | drospirenon /estetrol | |
| IL254734B1 (en) | Modified t cells and methods of making and using the same | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| PL3653221T3 (pl) | Przeciwciała anty-pvrig i sposoby ich zastosowania | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| EP3394250A4 (fr) | Reprogrammation cellulaire | |
| DK3149018T3 (da) | Neuroaktive steroider, sammensætninger og anvendelse deraf | |
| DK3663292T3 (da) | Diphenylmethan-derivat i krystallinsk form | |
| PL3319612T3 (pl) | Oksysterole i sposoby ich stosowania | |
| DK3329118T3 (da) | Forbedringer vedrørende vindmøllevinger | |
| DK3221332T3 (da) | Fremstilling af steroide fxr-modulatorer | |
| HUE054542T2 (hu) | Glükokortikoid receptor inhibitor | |
| EP3394078A4 (fr) | Inhibiteurs de récepteurs glucocorticoïdes | |
| HUE054337T2 (hu) | C-3 és C-17 módosított triterpenoidok HIV-1 inhibitorokként | |
| EP3394079A4 (fr) | Inhibiteurs de récepteurs glucocorticoïdes | |
| HRP20260035T1 (hr) | Akustična suhomontažna ploča | |
| DK3680243T3 (da) | Pentacyklisk forbindelse | |
| HUE042413T2 (hu) | Kompozíció helyi alkalmazásra a hallójáratban | |
| EP3126378A4 (fr) | Antagonistes de stéroïdes cardiotoniques et procédés associés | |
| DK3234275T3 (da) | Gipsplade med pcm-hukommelsesmateriale | |
| HUE053364T2 (hu) | Mikronizált formájú N-palmitoil-D-glükózamin | |
| ES1161411Y (es) | Panel solar |